Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

Frederik Persson, Julia B Lewis, Edmund J Lewis, Peter Rossing, Norman K Hollenberg, Hans-Henrik Parving, AVOID Study Investigators

    57 Citations (Scopus)

    Abstract

    Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).
    Original languageEnglish
    JournalDiabetes Care
    Volume33
    Issue number11
    Pages (from-to)2304-9
    Number of pages6
    ISSN0149-5992
    DOIs
    Publication statusPublished - 1 Nov 2010

    Fingerprint

    Dive into the research topics of 'Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy'. Together they form a unique fingerprint.

    Cite this